Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

Company plans to begin Phase IIb study in the first half of 2008

HOPKINTON, Mass., Jan. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has concluded enrollment in the Phase I/IIa clinical trial of Cethrin in acute spinal cord injury (SCI). A total of 48 subjects have been enrolled at 9 sites in the United States and Canada. We expect to release periodic updates of the data in 2008 following protocol-specified patient evaluations.

"We continue to be encouraged by the safety and efficacy observations of the trial. The rate and magnitude of improvement of many subjects seems greater than the expected pattern of recovery," commented Dr. Mark Hurtt, Alseres Chief Medical Officer. "The findings of the Phase I/IIa study serve as a strong foundation for the acceleration of our development plans for Cethrin."

Alseres intends to move forward with its previously announced plans for the placebo-controlled, Cethrin Phase IIb trial in acute spinal cord injury at sites in the U.S., Canada, Europe and other countries in 2008. "We believe that Cethrin continues to be the most advanced drug candidate in the clinic for the treatment of acute spinal cord injury in the world. If approved, Cethrin may offer hope for the nearly 11,000 new cases annually in the U.S. alone whose healthcare costs in the first year post-injury exceed $4 Billion," noted Dr. Mark Pykett, President and COO of Alseres. "We are pleased that the enrollment of the Phase I/IIa trial has concluded. Interim reported data have demonstrated encouraging safety and efficacy results over a 30-fold dose range. We look forward to the initiation of the Phase IIb trial in the first half of 2008."

Cethrin contains a prop
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Dynatronics Corporation (NASDAQ: ... has been appointed to the Company,s Board of Directors ... the death in November 2014 of board member Joseph ... Linder to our Board of Directors represents an important ... , chairman and president of Dynatronics.  "Rich is a proven ...
(Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... DIEGO , March 27, 2015   ... company, today announced new data showing that, compared ... TM technology provided highly equivalent interpretations of ... disease, and did so in a fraction of ... the way for more comprehensive genetic analysis in ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... People recovering,from acute heart problems such as ... develop habits to control heart attack risk factors ... to researchers at,Mayo Clinic in Rochester. These managers ... programs that last,three years. With these risk factors ...
... 4 AstraZeneca (NYSE:,AZN) today announced that it ... U.S. Food and Drug Administration (FDA) for approval ... Aerosol for the long-term maintenance treatment of asthma ... SYMBICORT is currently approved,for the long-term maintenance treatment ...
Cached Medicine Technology:Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 2Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 3Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 DrugDev ... Melissa (Liss) Easy was named to the 2015 Philadelphia ... Under 40 list spotlights 40 dynamic, up-and-coming leaders less ... and community involvement. Winners are honored at an awards ... of the Philadelphia Business Journal. , Lyn Kremer, Publisher ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global ... the SM1120 MEMS based ultra-miniature pressure sensor designed especially ... at only 220um x 75um provides ample space for ... With industry leading in vivo drift performance of ... broad operating pressure range from 0 to 1,100 mmHg ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... new study shows that monitoring levels of exhaled nitric oxide ... improve the course of their disease. , The study ... is funded by the National Institute of Allergy and Infectious ... The Sept. 20 issue of The Lancet reports ...
... GetResearchSmart LLC serves as Guest Editor for a special issue of ... entitled Measuring Trust in Clinical Research. , ... St. ... of The Monitor, journal of the Association of Clinical Research Professionals ...
... ,do not board, list comes as a surprise to ... -- Thirty-three would-be air travelers with suspected or confirmed ... health "Do Not Board" list in the first year ... , Authorized under the Aviation and Transportation Security Act ...
... National Poll Shows Large Majority Supports Funding ... of the nation,s,largest veterans service organizations, representing ... Veterans, Affairs Committee Chairman Daniel,Akaka (D-Hawaii), House ... a group of bipartisan cosponsors for introducing,legislation ...
... a top concern for businesses of all sizes. Just when,employers ... these that complicate the enrollment:, -- Employees don,t ... of what their employer provides. -- Health ... -- A handful of employees who are located in remote ...
... WHITE PLAINS, N.Y., Sept. 18 Dee Snider,best known as ... Sister,is taking on a new lead role this year as ... is personal: two of his children were,born prematurely, and he,s ... Despite the wild-man image from his heavy metal days, Snider ...
Cached Medicine News:Health News:Monitoring exhaled nitric oxide does not help manage asthma 2Health News:Monitoring exhaled nitric oxide does not help manage asthma 3Health News:GetResearchSmart LLC Website Founder Honored as Guest Editor 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 3Health News:Historic Legislation to End Delays in Veterans Health Care Funding 2Health News:Historic Legislation to End Delays in Veterans Health Care Funding 3Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 2Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 3Health News:Dee Snider Joins March of Dimes Bikers for Babies(R) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: